Metagenomi, Inc. (MGX) AI Stock Analysis

• Market Cap: $56.07M
• Dividend Yield: N/A
• Average Volume (3M): 368.09K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.93
• Revenue Growth: -4.22%
• EPS Growth: 18.67%
• Country: US
• Employees: 202
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -0.68
• Shares Outstanding: 37,381,496
• 10 Day Avg. Volume: 419,939
• 30 Day Avg. Volume: 368,089
• PEG Ratio: -0.03
• Price to Book (P/B): 0.20
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.50
• Enterprise Value/Market Cap: 1.33
• Enterprise Value/Revenue: 0.36
• Enterprise Value/Gross Profit: 1.55
• Enterprise Value/Ebitda: -0.24
• 1Y Price Target: $11.50
• Price Target Upside: 666.67% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

Metagenomi, Inc. faces significant challenges despite strong revenue growth. The company's profitability issues, negative cash flow, and weak technical indicators weigh heavily on the stock's outlook. Although corporate events provide some positive sentiment, the substantial financial and operational hurdles remain the dominant factors affecting the stock's performance.

Positive Factors

Collaboration and Funding

Metagenomi also leverages several collaborations with Ionis and Affini-T, which could be a good source of continued non-dilutive funds as development advances.

Gene Editing Innovation

The company could be a leader in the gene editing space and the current valuation of MGX is viewed as attractive for its disruptive potential.

Therapy Safety Profile

The therapy continues to have a favorable safety and tolerability profile.

Negative Factors

Financial Performance

MGX reported a Q1 net loss of $25MM and had cash of $226MM.

Regulatory Timeline

MGX plans to engage with regulators in 2025, and an IND/CTA for MGX-001 remains on track for 2026.

Metagenomi, Inc. Business Overview & Revenue Model

Company Description

Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

How the Company Makes Money

Metagenomi, Inc. generates revenue primarily through collaborations and partnerships with pharmaceutical and biotechnology companies. By licensing its proprietary gene editing technologies, Metagenomi earns milestone payments and royalties from the successful development and commercialization of therapeutics based on its innovations. Additionally, the company may engage in research and development agreements, providing expertise and access to its advanced CRISPR systems to partners, contributing further to its revenue streams. Strategic alliances and partnerships play a crucial role in enhancing Metagenomi's financial performance and market reach.

Metagenomi, Inc. Financial Statement Overview

Summary

Metagenomi, Inc. exhibits strong revenue growth, yet struggles with profitability and cash flow management. The balance sheet shows improving equity but requires careful monitoring of debt levels and liquidity. Overall, the company needs to address its operational and cash flow challenges to sustain its growth trajectory and ensure long-term financial health.

Income Statement

Metagenomi, Inc. has shown substantial revenue growth over the past years, with a remarkable increase from $243K in 2021 to $52.3M in 2024. However, the company is facing significant profitability challenges, as indicated by negative EBIT and net income margins, suggesting high operational costs or investments outpacing revenue growth. The gross profit margin improved significantly, but the net profit margin remains negative, indicating ongoing losses.

Balance Sheet

The company's balance sheet shows a strong equity position with positive stockholders' equity in 2024, recovering from negative equity in previous years. The debt-to-equity ratio is relatively low, reflecting manageable leverage levels. However, the consistent negative equity in earlier years and the volatility in asset management could pose risks to financial stability.

Cash Flow

Metagenomi's cash flow statement highlights significant cash outflows, particularly in operating cash flow, which has been negative and worsening. The free cash flow is also negative, indicating potential liquidity challenges. Despite these concerns, the company has maintained substantial cash balances, possibly from financing activities, but sustainability may be an issue if cash burn continues.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement		Total Revenue
52.30M	44.76M	17.20M	243.00K
	Gross Profit
46.89M	-49.65M	15.47M	-144.00K
	EBIT
-88.90M	-78.49M	-44.64M	-23.95M
	EBITDA
-83.49M	-74.28M	-39.19M	-20.75M
	Net Income Common Stockholders
-78.06M	-68.25M	-43.59M	-21.44M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
248.31M	271.18M	362.13M	108.15M
	Total Assets
324.60M	364.84M	414.49M	141.99M
	Total Debt
45.78M	48.23M	18.57M	48.93M
	Net Debt
18.39M	-92.37M	-165.87M	9.63M
	Total Liabilities
89.74M	500.43M	488.91M	174.54M
	Stockholders Equity
234.86M	-135.58M	-74.43M	-32.54M
Cash Flow		Free Cash Flow
-112.19M	-101.22M	15.75M	21.35M
	Operating Cash Flow
-109.07M	-91.41M	29.72M	24.26M
	Investing Cash Flow
-88.16M	45.73M	-122.20M	-74.32M
	Financing Cash Flow
84.01M	1.01M	239.59M	39.92M

Metagenomi, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MGX, the sentiment is Negative. The current price of 1.5 is below the 20-day moving average (MA) of 1.60, below the 50-day MA of 1.62, and below the 200-day MA of 2.38, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 48.51 is Neutral, neither overbought nor oversold. The STOCH value of 53.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MGX.

Metagenomi, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	56 Neutral	$4.71B	21.10	-19.41%	5.13%	16.77%	-32.41%
ADAP	45 Neutral	$70.13M	―	-273.36%	―	883.05%	62.93%
IMAB	45 Neutral	$69.37M	―	-22.38%	―	―	―
IOBT	43 Neutral	$64.56M	―	-138.78%	―	―	32.77%
MGX	43 Neutral	$56.07M	―	-31.93%	―	-4.22%	18.67%
INZY	37 Underperform	$87.16M	―	-141.69%	―	―	-17.06%

Metagenomi, Inc. Corporate Events

Metagenomi Showcases Genome Editing Advances at ASGCT 2025

On May 14, 2025, Metagenomi, Inc. announced the presentation of three abstracts at the ASGCT 28th Annual Meeting, showcasing advancements in genome editing technologies. The data highlighted the potential of their compact nucleases for efficient gene editing and the CAST system for precise large gene integration, marking significant progress in developing in vivo precision medicines. These advancements could impact the treatment of neurological disorders and other diseases caused by loss-of-function mutations, enhancing Metagenomi’s position in the gene editing industry.

The most recent analyst rating on (MGX) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Metagenomi, Inc. stock, see the MGX Stock Forecast page.

Spark’s Take on MGX Stock

According to Spark, TipRanks’ AI Analyst, MGX is a Neutral.

Metagenomi, Inc. shows robust revenue growth, but significant challenges remain in profitability and cash flow management. The technical analysis indicates a bearish trend, while the valuation reflects potential financial distress due to negative earnings. Positive corporate developments provide some optimism, yet the overall financial and operational hurdles weigh heavily on the stock’s outlook.

To see Spark’s full report on MGX stock, click here.

Metagenomi, Inc. Reports Q1 2025 Financial Results

Metagenomi, Inc. announced its first quarter 2025 financial results and business updates, highlighting a study on Hemophilia A that showed sustained factor VIII activity in nonhuman primates over 19 months, indicating potential for long-term therapeutic effects. The company is well-capitalized with $226 million in cash and securities, expected to support operations into 2027, and continues to advance its AI-driven metagenomics platform, with plans for further studies and technological enhancements.

The most recent analyst rating on (MGX) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Metagenomi, Inc. stock, see the MGX Stock Forecast page.

Spark’s Take on MGX Stock

According to Spark, TipRanks’ AI Analyst, MGX is a Neutral.

Metagenomi, Inc. shows robust revenue growth, but significant challenges remain in profitability and cash flow management. The technical analysis indicates a bearish trend, while the valuation reflects potential financial distress due to negative earnings. Positive corporate developments provide some optimism, yet the overall financial and operational hurdles weigh heavily on the stock’s outlook.

To see Spark’s full report on MGX stock, click here.

Metagenomi Reports 2024 Financial Results and Updates

Metagenomi, Inc. reported its full-year 2024 financial results and business updates, highlighting significant progress in its genetic medicine programs. The company declared a development candidate for hemophilia A, demonstrated sustained Factor VIII activity in nonhuman primates, and advanced its Ionis collaboration in cardiometabolic indications. With a strong cash position of $248.3 million, Metagenomi is well-capitalized to support its operations into 2027, aiming to file IND submissions in 2026 for its hemophilia A program and continue advancing its pipeline.